Pancreatic cancer is deadly and difficult to treat. A new pill could change that
RSS SUMMARY · AGGREGATED FROM PBS NEWS
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
Continue Reading
The full story continues on PBS News.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
PBS NEWS
World News
’60 Minutes’ in turmoil after longtime correspondent Scott Pelley is fired
PBS NEWS·2h ago·3 min read
World News
Iranian strikes set Kuwait’s largest airport ablaze amid fragile ceasefire with the U.S.
PBS NEWS·1h ago·3 min read
World News
Trump administration dismantles ambitious ocean monitoring program
PBS NEWS·2h ago·3 min read
World News
Health workers struggle to contain Ebola outbreak
PBS NEWS·2h ago·3 min read
Related
On this beat
World News
Students using phones, smart watches and glasses to cheat in exams, regulator warns
INDEPENDENT·1h ago·3 min read
World News
’60 Minutes’ in turmoil after longtime correspondent Scott Pelley is fired
PBS NEWS·2h ago·3 min read
World News
Iranian strikes set Kuwait’s largest airport ablaze amid fragile ceasefire with the U.S.
PBS NEWS·1h ago·3 min read
World News
Endangered sheep dies after getting entangled in razor wire at the border, biologist says
LAT·1h ago·3 min read